PDL BIOPHARMA, INC.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1986-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.pdl.com
Clinical Trials
35
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- PDL BioPharma, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00355901
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- PDL BioPharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00281294
- Locations
- 🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸Stanford University Medical Center-Div. of Rheumatology, Palo Alto, California, United States
🇺🇸Denver Arthritis Clinic, Denver, Colorado, United States
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- PDL BioPharma, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT00109161
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Sutter East Bay Medical Foundation, Berkeley, California, United States
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
- Conditions
- MelanomaMetastases
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- PDL BioPharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00099970
- Locations
- 🇺🇸
University of Alabama at Birmingham-Comprehensive Cancer Ctr., Birmingham, Alabama, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UCLA School of Medicine, Los Angeles, California, United States
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-06-10
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- PDL BioPharma, Inc.
- Registration Number
- NCT00014664
- Locations
- 🇺🇸
Protein Design Labs, Inc., Freemont, California, United States